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g Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L’Hospitalet de Llobregat, 
Barcelona, Spain 
h Department of Diagnostic Imaging, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L’Hospitalet de Llobregat, 
Barcelona, Spain 
i Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L’Hospitalet de Llobregat, 
Barcelona, Spain 
j Department of BUH-ICO-IDIBELL Biobank, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain 
k Department of Statistics, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain 
l Department of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L’Hospitalet de 
Llobregat, Barcelona, Spain 
m Department of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de 
Llobregat, Barcelona, Spain 
n Evaluation of Health Determinants and Health Policies Group, Hestia Chair in Integrated Health and Social Care, School of Medicine, Universitat Internacional de 
Catalunya, Barcelona, Spain   








A B S T R A C T   
Introduction: Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome 
triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of 
immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that 
methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe 
COVID-19 patients. 
Methods: and analysis: TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the ef-
ficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in 
patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. 
Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess 
the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature 
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≤37.5 ◦C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive 
hours. 
Discussion: Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing 
into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast 
effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the 
secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, 
if effective and safe, a large number of patients could be treated in developed and developing countries. 
Trial registration number: NCT04341038 / EudraCT: 2020-001445-39   
1. Background 
In December 2019, an emerging disease (COVID-19), caused by a 
newly identified human coronavirus (SARS-CoV-2), was first recognized 
in Wuhan, China and spread worldwide [1,2]. The WHO declared the 
COVID-19 epidemic to be a pandemic on March 12, 2020 [3]. 
Unfortunately, there are still no proven effective and safe therapies 
for treating the COVID-19 illness other than supportive care. Despite the 
lack of evidence, the urgency of care leads to a large number of severe 
patients receiving off-label and compassionate use therapies, based on 
their in vitro antiviral or immunomodulatory properties. Among sug-
gested treatments, the repositioning of older drugs may be a plausible 
strategy given that their proven safety profile [4,5]. Furthermore, there 
are several ongoing randomized controlled trials (RCTs) assessing 
different drug regimens for treating patients with COVID-19 [6]. 
Of great concern, some COVID-19 patients evolve to fatal lung injury 
and multi-organ failure due to the serious inflammatory process trig-
gered by the viral infection [7–12]. While the use of some immuno-
suppressive drugs has been reported to be potentially harmful, other 
such drugs, paradoxically, have been justified in treating the excessive 
inflammation triggered by the viral infection [13]. Unfortunately, 
studies performed following pragmatic randomized controlled trials 
(pRCT) are still very limited to date and current international recom-
mendations have not taken a position either in favor of or against the use 
of immunomodulatory therapy in such patients. 
Our working hypothesis is that methylprednisolone pulses and 
tacrolimus might be an effective and safe drug combination strategy for 
severe COVID-19 patients. Accordingly, given the rapid spread of 
COVID-19 and the current health emergency worldwide, we performed 
a proof-of-concept study in a randomized, open-label, single-center, 
clinical trial to evaluate the efficacy and safety of methylprednisolone 
and tacrolimus plus standard of care (SoC), versus SoC alone, in severe 
COVID-19 patients with lung injury and systemic hyperinflammatory 
syndrome. 
The rationale for the present pRCT is based on the fact that gluco-
corticoids such as methylprednisolone are a mainstay in the treatment of 
several immune-mediated disorders, with multiple mechanisms of ac-
tion involving both the humoral and cell-mediated arms of immunity. As 
for tacrolimus, the rationale for its use is based on its specific mechanism 
of action leading to an impaired lymphocyte function and a decrease in 
pro-inflammatory cytokines (PIC) [14]. Interestingly, severe COVID-19 
disease presents a fairly similar clinical and cytokine profile to other 
diseases such as secondary hemophagocytic lymphohistiocytosis (sHLH) 
[15] or clinically amyopathic dermatomyositis (CADM) associated with 
anti-melanoma differentiation-associated gene 5 (MDA-5), where cal-
cineurin inhibitors such as tacrolimus or cyclosporine play a central role 
in its treatment [16]. Furthermore, some human coronavirus (CoV) 
replication depends on active immunophilin pathways, which can be 
inhibited by tacrolimus, at low, non-cytotoxic concentrations in cell 
culture [17]. In this regard, anecdotal case series suggest that tacrolimus 
may exert a protective effect in solid organ transplanted patients 
affected by MERS-CoV [13]. Thus, tacrolimus has an immunosuppres-
sive effect but would also block viral replication and may have beneficial 
impacts on severe COVID-19 lung injury. 
2. METHODS: (no word limit) 
2.1. Study design 
TACROVID is a pragmatical, randomized (1:1), open-label, single- 
center, phase II clinical trial to evaluate the efficacy and safety of 
methylprednisolone pulses and tacrolimus plus SoC, versus SoC alone, in 
severe COVID-19 patients with lung injury and systemic hyper-
inflammatory syndrome. 
2.2. Population 
Patients are being prospectively recruited and included in the study 
for subsequent randomization, if they meet all the inclusion criteria and 
there is no reason for exclusion. 
Abbreviations 
CoV = Coronavirus 
SARS-CoV = Severe Acute Respiratory Syndrome Coronavirus 
MERS-CoV = Middle East Respiratory Syndrome Coronavirus 
SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2 
COVID-19 = Coronavirus disease 2019 
SoC = Standard of Care 
PaO2 = arterial oxygen partial pressure 
SatO2 = Oxygen saturation 
FiO2 = fractional inspired oxygen 
PIC = pro-inflammatory cytokines 
HLH = hemophagocytic lymphohistiocytosis 
CADM = clinically amyopathic dermatomyositis 
MDA-5 = anti-melanoma differentiation-associated gene 5 
RT-PCR = Reverse transcription polymerase chain reaction 
LDH = lactate dehydrogenase 
CRP = c-reactive protein 
ALT = alanine aminotransferase 
ICF = informed consent form 
ECMO = extracorporeal membrane oxygenation 
GFR = Glomerular filtration rate 
BMI = body mass index 
PSI = Pneumonia Severity Index 
SOFA score = Sequential Organ Failure Assessment Score 
6MWT = 6-min walk test 
eCRF = electronic case report form 
ARDS = acute respiratory disease syndrome 
JAK = Janus Kinase 
IL = interleukin 
BUH = Bellvitge University Hospital  
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2.2.1. Inclusion criteria  
1) COVID-19 infection confirmed by nasopharyngeal RT-PCR,  
2) New pulmonary infiltrates (either by chest X-ray or computerized 
axial tomography),  
3) Respiratory failure (PaO2/FiO2 <300 or satO2/FiO2 <220),  
4) High analytical inflammatory parameters (CRP >100 mg/L, and/or 
D-Dimer >1000 μg/L and/or Ferritin >1000 μg/L). 
2.2.2. Exclusion criteria  
1) Critically ill patients with life expectancy ≤24h,  
2) Glomerular filtration ≤30 mL/min/1.73 m2,  
3) Leukopenia ≤4000 cells/μL or other conditions that cause 
immunosuppression,  
4) Concomitant potentially serious infections, 
5) Contraindication for the use of corticosteroids or tacrolimus ac-
cording to the Summary of Product Characteristics,  
6) Known hypersensitivity to any of the study drugs, their metabolites, 
or formulation excipient,  
7) Previous participation in a RCT in the last 3 months. 
All patients (or a legal representative) have to provide informed 
consent (ICF) prior to initiation of the study procedures. 
2.3. Setting 
The TACROVID trial is being conducted at Bellvitge University 
Hospital (BUH), a 750-bed tertiary care public hospital in Barcelona 
(Catalonia, Spain). BUH is the reference hospital for high complexity 
patients from the Southern Area of Catalonia, a region of approximately 
2 million inhabitants. 
2.4. Randomization 
On day 0, patients are centrally and randomly assigned using the 
RedCap computer platform that allows data collection and patient 
randomization. Patients are not stratified by baseline variables. Partic-
ipants are randomized in a 1:1 ratio into one of two study groups: 
methylprednisolone pulses, tacrolimus and SoC, or SoC alone. 
2.5. Treatment 
Patients are being randomly assigned to one of the following arms: 
1. Experimental: methylprednisolone pulses of 120 mg/day are 
administered on 3 consecutive days (if not previously administered) 
and immediate release tacrolimus is administered twice daily until 
clinical stability is achieved. Tacrolimus dosing is individualized 
through therapeutic drug monitoring (TDM) to achieve blood trough 
levels of 8–10 ng/mL. In addition, patients in the experimental arm 
can receive standard of care (SoC) for their management in accor-
dance with treating physicians. 
2. Control (SoC): SoC includes measures of supplemental oxygen and 
respiratory support, fluid therapy, antipyretic treatment, postural 
measures, low molecular weight heparins, and may also include 
other treatments, whether antiviral or immunosuppressive drugs, or 
those necessary at the discretion of the treating physician, except for 
cyclosporine and/or tacrolimus. 
The experimental drugs start immediately after having been 
randomly assigned to this group. The experimental treatment is dis-
continued after “clinical stability”, which is achieved after fulfilling all of 
the following criteria for 48 consecutive hours: body temperature 
≤37.5 ◦C; PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300; and respiratory 
rate ≤24 rpm. 
Experimental treatment is also discontinued if the included patient 
has a severe or potentially severe infection, required invasive mechan-
ical ventilation, extracorporeal membrane oxygenation (ECMO), or has 
any serious medication-related adverse event (of special interest re-
fractory HTA, decrease of more than 50% of the GFR compared to the 
baseline, or ventricular tachycardia). 
2.6. Study visits 
All patients are followed from day 0 through day +56 or death. The 
planned visits are: 1) randomization visit (day 0) in which the patient is 
screened and eventually included in the study; 2) Hospitalization visits 
that are variable according to the period of admission; 3) Visits on day 
+28 ± 3 and on day +56 ± 3 from randomization. These visits are face- 
to-face to evaluate whether patients present a relapse or worsening of 
the disease, as well as the presence of adverse events or mortality. 
Specific procedures that are performed on each visit are detailed in 
Table 1 and the evaluation methods section. 
2.7. Evaluation methods 
2.7.1. Clinical parameters 
The randomization visit (day 0) includes the collection of de-
mographic variables [date of birth, sex, ethnicity], weight and height, 
clinical data [symptoms onset date, hospital admission date, clinical 
manifestations, radiological characteristics of pulmonary infiltrates], 
comorbidities [smoking and alcohol consumption, Charlson index], 
Table 1 
Flow-chart of the trial showing the procedures that will be conducted in each 
visit.   
Randomization 
visit (day 0) 
Hospitalization 
visits (days n) 
Visit 28 
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COVID-19 
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Vital signs x x x x 
8-point Ordinal 
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x x x x 
Tacrolimus 
levels  
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Cytokines x x x x 
Viral load 
(blood) 
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Clinical stability x x x x 
Lung tests (x-ray, 




x x (1) x (1) x 
Study treatment x x x x 
Concomitant 
medication 
x x x x 
AE registration x x x x 
(1) according to the attending physician. 
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functional and cognitive assessment [Barthel and Pfeiffer index respec-
tively], 8-point Ordinal scale (https://clinicaltrials.gov/ct2/show/NC 
T04280705), vital signs [temperature, blood pressure, heart rate, res-
piratory rate, oxygen assessment and supply (type of oxygen mask and 
FiO2, non-invasive or invasive ventilator support devices, or ECMO, 
PaO2/FiO2 and/or SatO2/FiO2), and conscious level using the Glasgow 
Coma Scale], as well as concomitant medication. With all these data we 
automatically calculate body mass index (BMI), the Pneumonia Severity 
Index (PSI) and CURB-65 index, and determine the extent of organ 
failure (SOFA score). The hospitalization visits include the collection of 
vital signs, 8-point Ordinal scale, adverse events and mortality. Visits on 
day +28 ± 3 and +56 ± 3 include vital signs, ordinal scale, relapse or 
worsening of the disease, adverse events and mortality. 
2.7.2. Tests and other procedures 
A blood analysis is performed before starting the study treatment 
with the following biomarkers: 1) hematology (hemoglobin, hematocrit, 
platelet count, absolute lymphocyte count, leukocyte count with dif-
ferential) assessed using Sysmex® XN2000 analyzer (Sysmex Europe 
GmbH; Norderstedt; Germany); 2) basic chemistry (creatinine, albumin, 
ALT, total bilirubin) and inflammatory parameters (ferritin, D-dimer, 
CRP, LDH) measured with Cobas® 6000/8000 analyzer (Roche Di-
agnostics®, Risch-Rotkreuz, Switzerland), which has spectrophotometry 
and immunochemistry modules with electrochemiluminescent detec-
tion; and 3) coagulation (activated partial thromboplastin time, pro-
thrombin time and fibrinogen) using ACLTOP® 550 analyzer (Werfen®; 
Barcelona, Spain). Furthermore, all patient samples are collected, pro-
cessed and stored at randomization, and weekly after randomization by 
the BUH-IDIBELL Biobank following standard operating procedures. 
During hospitalization, a blood analysis is performed 3 times a week 
with the same parameters as used at randomization. Tacrolimus levels 
are measured using a method based on ultra-high-performance liquid 
chromatography coupled with tandem mass spectrometry (HPLC-MS/ 
MS) [18]. 
The QTc interval is evaluated using an ECG before randomization, 
and an electrocardiogram 3 times a week is recommended during hos-
pitalizations. All pulmonary tests performed during hospitalization at 
the discretion of the treating physician are being collected (chest x-Ray 
CT scan). A chest CT scan, the 6-min walk test (6MWT) and functional 
respiratory tests on day +56 ± 3 follow-up visit are performed. 
In addition, a follow-up oropharyngeal SARS-CoV-2 RT-PCR is per-
formed on day +28 ± 3 and +56 ± 3 visits. Blood viral load will be 
evaluated using quantitative RT-PCR to assess the impact of immuno-
suppressive treatment on viral dynamics. Microbiological tests are being 
carried out by the Microbiology Department at the BUH. 
All samples will be sent to the Immunology Laboratory of the 
Biomedical Diagnostic Center at the Clinic Hospital in Barcelona to 
perform a multiple cytokines quantification technique by Luminex®. 
Concentration of the following cytokines will be analysed: IL-6, IL-18, 
CXCL10, CXCL9, TNF-alpha, IFN-alpha, IFN-beta, IFN-gamma, IL1RA, 
IL1-beta, IL10 and IL-2R/CD25. 
2.8. Outcomes 
2.8.1. Primary end point 
Average of days until clinical stability from treatment randomization. 
Treatment failure is defined as: 1) patient who does not meet the 
criteria for clinical stability 56 days after starting treatment; 2) patient 
presenting with a grade 3 or 4 adverse event attributed to trial treat-
ment; or 3) patient who dies after being included in the clinical trial. 
2.8.2. Secondary endpoints  
- Days until normalization of each of the clinical parameters (body 
temperature, PaO2/FiO2 and/or SatO2/FiO2, respiratory rate) from 
day +1 through day +56.  
- Days until normalization of each of the analytic parameters (D- 
dimer, CRP, ferritin, LDH, IL-6) from day +1 through day +56.  
- Number of patients requiring non-invasive and invasive ventilatory 
support devices during hospitalization.  
- Clinical status according to the 8-point Ordinal scale from day +1 
through day +56.  
- Number of patients who reach a clinical status ≤2 after 10 days or 
hospital discharge, whichever is first.  
- Number of patients who reach clinical stability after 10 days or 
hospital discharge, whichever is first.  
- Value of each of the analytical values (D-dimer, CRP, ferritin, LDH, 
IL-6) after 10 days or hospital discharge, whichever is first.  
- Days with trial experimental treatment.  
- Days until hospital discharge.  
- Changes in blood quantitative viral load by RT-PCR before start 
treatment and weekly during hospitalization.  
- Changes in expanded cytokine profile before starting treatment and 
weekly during hospitalization.  
- Long-term efficacy (28 and 56 days after trial treatment initiation) 
measuring whether clinical stability are maintained and the inci-
dence of relapse of COVID-19 illness.  
- Description of the radiological abnormalities (chest x-ray, chest CT 
scan, functional tests) at day 56.  
- Adverse events according to their severity and relationship to trial 
experimental treatment.  
- COVID-19 related mortality at day +28 and + 56 after 
randomization.  
- All-cause mortality at day +28 and + 56 after randomization. 
2.8.3. Criteria for withdrawing a patient from the study 
Patients must be withdrawn from the study in any of the following 
situations: 1) any adverse event for which clinicians consider it neces-
sary to withdraw trial experimental therapy; 2) the patient requests to be 
withdrawn from the study (at any time during the patient’s participa-
tion); 3) the principal investigator (PI) considers that there has been a 
serious protocol violation; 4) lost to follow-up; and 5) pregnancy during 
the study. 
When a patient withdraws from the study, the investigator records 
the reason/s in the clinical chart and the electronic case report form 
(eCRF). If the reason for withdrawal is a serious adverse event, the pa-
tient must be followed-up until resolution or stabilisation of the event. 
Patients who withdraw will not be replaced. 
2.9. Statistical analysis 
2.9.1. Determination of sample size 
The median time to clinical stability in the control group is expected 
to be 16 days. If the hazard ratio of clinical stability of control patients in 
relation to the patients in the experimental group were 0.52, it would be 
necessary to include 42 patients in each group in order to be able to 
reject the null equality hypothesis with a power of 80%. The probability 
of Type I error associated with this hypothesis test is 0.05 and includes 
5% of withdrawal. 
2.9.2. Statistical considerations 
A descriptive analysis of the study variables will be carried out. 
Continuous variables will be described as mean and Standard Deviation 
(SD) or as median and range; and categorical variables as absolute fre-
quencies and percentages. The main analysis will be performed when all 
patients reach clinical stability or failure. If patients are in hospital for 
56 days, they will be considered clinical failures. Comparison between 
average time to achieve clinical stability between the two study groups 
will be measured using the log-rank test. To quantify the degree of as-
sociation, hazard ratio will be estimated with a Cox proportional haz-
ards model using a 95% confidence interval. 
Efficacy analyses will be performed for the intention to-treat (ITT) 
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population. If a proportion of subjects >10% is detected to have relevant 
deviations from the protocol (for example, non-compliance with the 
selection criteria, non-compliance or inability to receive the trial treat-
ment), the per protocol (PP) analysis will exclude those subjects with 
such deviations. If this group is defined, all exploratory efficacy analyses 
will be repeated as a sensitivity test. 
As additional analysis, a Cox proportional hazards model, adjusted 
for clinically relevant confounding factors such as age, sex, comorbid-
ities using the Charlson index, indexes to assess the severity of pneu-
monia (PSI and CURB-65), index of organic dysfunction (SOFA) and 
inflammatory parameters will be performed. In addition, prespecified 
subgroup analyses involving sensitivity analysis will be used to evaluate 
outcomes in patients not receiving invasive mechanical ventilation. 
For evaluation of secondary variables, we will calculate unadjusted 
and adjusted estimations of effect size and the corresponding 95% 
confidence intervals using linear, logistic or proportional hazards Cox 
regression. Study adverse events will be described according to their 
severity and relationship with other treatments, and will be compared 
between treatment groups. Midway through recruitment, i.e. 21 patients 
per arm, an intermediate efficacy and safety analysis will be performed. 
For this, a correction of the type I error will be applied following Lan- 
DeMets (O’Brien – Fleming) in evaluation of efficacy. 
The IDIBELL Biostatistical Unit will perform analysis and analysts 
will be blind to the treatment received by the patients (intervention vs. 
usual care). R version 3.6.2 or higher for Windows (R Foundation for 
Statistical Computing, http://www.r-project.org) will be used for data 
treatment and analysis. 
2.10. Monitoring 
An electronic case report form (eCRF) has been created using the 
RedCap computer platform. IDIBELL Clinical Research and Clinical 
Trials Unit (UICEC-IDIBELL) is carrying out the monitoring of the trial. 
Regular monitoring is performed by the UICEC IDIBELL according to the 
ICH GCP. Compliance with the approved protocol and verification of 
data is evaluated according to applicable regulatory requirements. The 
key data in the Monitoring Plan are those related to informed consent, 
primary outcome, mortality and safety data. 
2.11. Adverse events reporting and quantification 
2.11.1. Definitions  
● Adverse event (AE): any injury related to medical management 
(including all aspects of care) that occurs during the patient’s 
participation in the clinical trial will be considered an adverse event. 
An adverse event may be related to the study medication or be non- 
related.  
● Adverse drug reaction (AR): any ‘adverse drug event’ that occurs when 
the medication is used as directed and in the usual dosage will be 
considered an adverse drug reaction.  
● Serious AE (SAE) or serious AR (SAR) are considered to be those that 
at any dose:  
- provoke death (Note: death is a possible evolution of SARS-CoV-2 
infection);  
- put patient’s life at risk;  
- require the patient’s hospitalization or the extension of an existing 
hospitalization.  
- cause permanent or significant disability or incapacity;  
- cause a congenital anomaly or malformation;  
- are considered medically relevant.  
● Adverse drug event of particular interest for the study: The investigator 
shall record in the eCRF and communicate to the promoter, the AE 
that are considered of special interest as soon as possible and no later 
than 15 days after he becomes aware of them. The AEs that are 
considered of special interest are:  
- refractory hypertension (defined as poor blood pressure control 
despite 3 antihypertensive drugs including a diuretic);  
- renal impairment (decrease of more than 50% of the GFR compared 
to the baseline);  
- ventricular tachycardia. 
2.11.2. Reporting 
The UICEC-IDIBELL is carrying out pharmacovigilance of the trial. 
All SAEs (including death), regardless of their relationship with the 
investigational medications, have to be notified by the investigator 
within 24h. The investigator has to make the notification via the SAE 
Notification Form, sending it by email to the pharmacovigilance unit 
that will review it and, if appropriate, will request additional informa-
tion from the investigator. The investigator will provide information to 
the promoter or pharmacovigilance unit whenever requested and, in any 
case, when its initial evaluation changes regarding severity or causation. 
Likewise, all additional information regarding the AE, until the end of 
the study or until its definitive outcome, must be communicated without 
delay, via follow-up reports following the notification procedure pre-
viously described. 
In case of a suspected unexpected serious adverse reaction (SUSAR), 
UICEC-IDIBELL will report to the competent authorities. The sponsor 
will also report the development update safety report (DSUR) once a 
year to the ethics committee and the Spanish Agency for Drugs and 
Health Products (AEMPS). 
2.12. Ethical considerations 
This trial conforms to the Declaration of Helsinki and Good Clinical 
Practice guidelines, and personal data protection as required by Spanish 
law (LOPD 3/2018). The protocol and informed consent form (ICF) were 
approved by the BUH’s Ethical Committee for Drug Research (EC) and 
by the Spanish Agency for Drugs and Health Products (AEMPS) in March 
2020, in accordance with current legislation, Royal Decree 1090/2015 
of December 4 and European Regulation 536/2014 of April 16, regu-
lating clinical trials with drugs. 
The patient, his or her closest legal or family representative (in case 
of incapacity due to the severity of the clinical situation) has to accept 
the ICF. As patients with COVID-19 can infect researchers via the ICF 
document, patients can consent orally with a witness, and this is docu-
mented in the patient’s medical history. If the legal representative or a 
close relative is in quarantine due to COVID-19 quarantine, informed 
consent is provided orally by telephone and documented in the patient’s 
medical history. The written ICF is obtained when the patient or his/her 
closest legal or family representative are able to give consent, as they are 
not quarantined. 
Methylprednisolone and tacrolimus are commercially available as 
generic drugs, so no special permissions are required. Both the promoter 
and the center are respectively responsible for the treatment of patient 
data and commit to comply with Regulation (EU) 2016/679 of the Eu-
ropean Parliament and of the Council of April 27, 2016 on Data Pro-
tection (RGPD), as well as with all other laws and regulations in force 
and applicable (Organic Law on Protection of Personal Data and Guar-
antee of Digital Rights 3/2018 of December 05). The data collected for 
the study are identified by a code, so as not to include any information 
that can identify the patient (name, surname, initials, address, social 
security number, etc.). Only the study clinician/collaborators are able to 
relate such data to the patient and his/her medical history. Therefore, a 
patient’s identity is not revealed to any other person except the health 
authorities when required, or in the case of medical emergency. Access 
to patient information is restricted to the attending physicians, the 
health authorities AEMPS, the Clinical Research Ethics Committee, and 
personnel authorised by the sponsor when they need to check the data 
and procedures used in the study, always maintaining confidentiality in 
accordance with current legislation. If participants wish to know more, 
they can contact the Promoter’s Data Protection Officer. 
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2.12.1. 1 Protocol amendments 
The protocol was approved by the EC and the AEMPS on March 31, 
2020, in a process of authorization adapted to the pandemic situation 
and based on a protocol synopsis (March 28, 2020). A substantial 
amendment to the original protocol was submitted to the EC and the 
AEMPS in accordance with Spanish legislation, and accepted on April 9, 
2020. We decided to reduce tacrolimus plasma levels from 10 to 15 to 
8–10 ng/mL and not to maintain corticosteroids by protocol beyond the 
three pulses of methylprednisolone in the experimental group. In addi-
tion, some exclusion criteria were added, such as glomerular filtration 
≤30 mL/min/1.73m2, leukopenia ≤4000 cells/μL or other conditions 
that cause immunosuppression, and concomitant and potentially serious 
infections. Another additional amendment was accepted by the EC and 
AEMPS on May 25, 2020, including a complete clinical study protocol 
with new secondary key outcomes (8-point Ordinal scale and radiolog-
ical abnormalities) that are being analysed in several COVID-19 clinical 
trials. These outcomes are being prospectively reported in the trial’s 
eCRF, but were not reported in the protocol synopsis. We do not remove 
any of the previous key study outcomes. 
2.13. Publication plans 
The trial is currently actively recruiting patients. Completion of pa-
tient recruitment is expected for Q3-Q4 of 2020. The sponsor commits 
itself to publishing the data within 12 months of completion of the study. 
Results will be analysed and reported in accordance with CONSORT 
guidelines. 
3. Discussion 
Clinically, COVID-19 patients can evolve into 3 stages of progressive 
severity. Viral incubation and early establishment of the disease are the 
predominant components in the first week from the onset of symptoms. 
In the second stage, viral replication and transition into moderate acute 
lung involvement are the most important components. The third and 
most advanced stage manifests as severe pulmonary injury and systemic 
multi-organ failure, resulting from cytokine storm and systemic hyper-
inflammatory response. Older age, comorbid chronic conditions, 
elevated body mass index, lymphopenia, and elevated transaminases, 
LDH, D-dimer, ferritin, and soluble IL-2 receptor (sIL-2R) on admission 
are some of the reported risk factors associated with higher mortality 
[7–12]. From a pathological viewpoint, two different pathological 
mechanisms appear to coexist in the COVID-19 illness; the first, trig-
gered by the virus itself, and the second, by the host-immune response. 
Accordingly, a two-step sequence of antiviral and anti-inflammatory 
drug administration has been proposed, regarding the natural 3-stage 
evolution of COVID-19 disease [19]. 
Despite randomized clinical trials (RCTs) being the only way to find 
effective and safe treatments, very limited available RCTs for treating 
COVID-19 have been reported to date [20]. Given the emergency situ-
ation, most patients are receiving compassionate, unproven therapies to 
avoid clinical progression into severe advanced stages where 
host-immune inflammatory response is the most important component 
[21]. 
Several studies demonstrate that cells infected by coronavirus (CoV) 
produce elevated levels of PICs in order to tackle the invading virus. The 
overproduced PICs may cause immuno-mediated damage to the lungs 
and other organs, resulting in severe lung injury and systemic hyper-
inflammatory syndrome [22]. Once this excessive inflammatory 
response has been triggered, it may self-perpetuate in some patients 
despite a decrease in the CoV viral load. So, it may be necessary to add 
"anti-inflammatory" treatments such as corticosteroids, anti-IL-6 or 
anti-IL-1 inhibitors, Janus kinase (Jak) inhibitors, polyclonal immuno-
globulins, etc. to reduce the secondary deleterious inflammatory 
response triggered by the virus [6]. 
In this regard, glucocorticoids appear as a key first-line option, 
especially given their worldwide availability and cost. However, their 
use has been controversial in patients with SARS-CoV, MERS-Cov or 
influenza infections. On the one hand, intravenous steroid use has been 
associated with delayed elimination of coronaviruses in the blood and 
lungs of patients with MERS-CoV [23] and SARS-CoV [24], and steroids 
associated with an increased risk of mortality and adverse events in 
influenza patients [25–27]. On the other hand, a Cochrane review of 
glucocorticoids as adjunctive therapy in influenza found evidence of low 
quality due to confounding by indication [28], and there are some series 
which suggest improvement of severe COVID-19 lung injury after 
administration of steroids [8,10]. 
Furthermore, a small retrospective observational study conducted in 
China [29] suggests the efficacy of tocilizumab (an IL-6 inhibitor) in the 
treatment of 21 COVID-19 patients with severe pneumonia and high 
IL-6. But tocilizumab can cause even deeper immunosuppression than 
steroids, increasing the risk of sepsis, bacterial pneumonia, gastroin-
testinal perforation, and hepatotoxicity [20]. Another drawback of 
tocilizumab is its shortage in some hospitals worldwide and its high cost 
to national health systems. Interestingly, IL-1 blockade has shown 
particular promise in cytokine storm syndrome and high-dose regimens 
have been shown safe even in the context of overt sepsis [30]. Emapa-
lumab (anti-IFNγ) is FDA-approved for HLH and may be effective in 
COVID-19 inflammatory phase. JAK inhibition appears promising; 
however, the safety of this medication in severe viral infection remains 
unknown. Accordingly, some ongoing RCTs are studying glucocorticoids 
and blockage of IL-1, IL-6, and IFNγ in COVID-19 [6]. However, at the 
end of April 2020, no trials assessing calcineurin inhibitors, whether 
tacrolimus or cyclosporine, had been registered either at www.clinicalt 
rials.gov nor EU Clinical Trials Register, thus prompting us to carry out 
the present investigation. 
Given the scarcity of medical reports supporting the use of immu-
nosuppressive therapy in severe COVID-19, the TACROVID trial was 
initiated on March 29, 2020. The study is a pragmatical, randomized, 
open-label, single-center, phase II clinical trial to evaluate the effec-
tiveness and safety of methylprednisolone and tacrolimus in combina-
tion regimen plus SoC, versus SoC alone, in COVID-19 with severe lung 
injury and systemic hyperinflammatory syndrome. We decided to 
consider methylprednisolone pulses for their rapid onset of action, 
combined with the ability of tacrolimus to inhibit both the multiple PICs, 
and the SARS-CoV replication in cell cultures. Moreover, the rationale of 
our study is aligned with an Ovid MEDLINE review article [13] 
searching for current evidence for immune-suppressing or stimulating 
drugs to treat COVID-19, which concludes that low-dose methylpred-
nisolone and tacrolimus may have a beneficial impact in such COVID-19 
populations. 
Tacrolimus has been administered for decades to prevent allograft 
rejection in transplanted patients as well as to treat patients with severe 
autoimmune diseases, and it has a well-known safety profile. In addi-
tion, it is a low-cost drug and can be manufactured on a large scale. Thus, 
if tacrolimus is effective in treating the inflammatory process triggered 
by COVID-19, a large number of patients could be treated in developed 
and developing countries. Despite the fact that tacrolimus has been 
shown to be safe for other diseases, we [researchers] are particularly 
aware of the possible occurrence of associated AE throughout the pre-
sent TACROVID trial. In this respect, most patients in the advanced stage 
of the COVID-19 illness are currently given on immunosuppressive 
treatment and it is well-known that this facilitates certain opportunistic 
infections, making it difficult to attribute them to one particular drug. 
Moreover, the drawback of tacrolimus is that it may interact with some 
antiviral treatments used in COVID-19 (especially Lopinavir). Finally, 
tacrolimus is started when patients transition into the most severe 
clinical stage which, in turn, facilitates the occurrence of AE. 
Interestingly, in addition to its immunomodulatory effect, tacrolimus 
has been also reported to show certain in vitro activity against different 
human coronaviruses, inhibiting viral replication through immunophi-
lins, although its efficacy and safety have not been assessed in clinical 
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practice. For this reason, an interim analysis will be conducted when 
half of patients (21 per arm) will be recruited in order to measure the 
basal and weekly viral load, and the potential AE related to 
immunosuppression. 
Regarding the study design, the present trial was not designed as a 
double-blind trial. This was considered unrealistic given the emergency 
situation and the extensive workload that it would involve for the hos-
pital pharmacy service. For the above-mentioned reasons, the TACRO-
VID trial was designed as an open study which allows the use of all drugs 
that treating physicians prescribe, even without clear evidence to sup-
port their use. To minimize the impact of an open study, the primary 
end-point “time to clinical stability”, is based on objective, quantitative 
measures for 48 consecutive hours: body temperature, and PaO2/FiO2 
and/or SatO2/FiO2, and respiratory rate. Likewise, the statistician 
performing analysis is blind to the treatment that patient receives 
(experimental vs control). 
Cytokine measurement throughout the trial can reveal new available 
information on COVID-19 evolution and potential new treatment tar-
gets. IFNγ and IL-1β are very relevant cytokine in MAS, but they are not 
easily assessed in the peripheral blood. CXCL9, a stable chemokine, is a 
useful surrogate for IFNγ activity in MAS, as are IL-18 and IL-1RA for IL- 
1β. Thus, in this trial we will not only analyse how the cytokine profile 
evolves after treatment with tacrolimus, but we will also be able to 
detect increases in cytokines that can also be treated by other proven 
specific inhibitors (e.g. IL-18 with Tadekinig alpha, IFNγ with 
Emapalumab). 
In summary, the TACROVID trial assesses the combined use of 
tacrolimus and methylprednisolone, in addition to the standard of care 
in patients with severe COVID-19 illness. The aim is to evaluate both the 
beneficial effect of tacrolimus on controlling viral replication and, in 
combination with methylprednisolone pulses, modulating the host- 
immune inflammatory response triggered by the virus. In addition, po-
tential adverse events related to this immunosuppressive therapy are 
carefully followed-up throughout the investigation. The results of the 
present trial might encourage further RCTs to assess the efficacy and 
safety of new antiviral and anti-inflammatory drugs regimens, in 
sequential combination, at earlier clinical stages of COVID-19. 
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